NCT01877239View on ClinicalTrials.gov

Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria

CompletedOBSERVATIONAL
Enrollment

111

Participants

Timeline

Start Date

December 10, 2012

Primary Completion Date

January 7, 2016

Study Completion Date

June 14, 2016

Conditions
Rheumatoid Arthritis
Interventions
OTHER

non-intervention

observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC

Trial Locations (10)

1100

Rheumazentrum Oberlaa, Vienna

1130

Ordination Dr. Peter Peichl, Vienna

1170

Ordination Dr. Maya Thun, Vienna

2351

Ordination Dr. Thomas Schwingenschlogl, Wiener Neudorf

4020

Ordination Dr. Richard Janetschko, Linz

4030

Ordination Dr. Wilhelm Kaiser, Linz

4040

Dr. Eichbauer-Sturm, Linz

8010

Ordination Dr. Thomas Muller, Graz

8020

Barmherzige Brüder Graz Eggenberg, Graz

9020

Ordination Dr. Horst Just, Klagenfurt

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01877239 - Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria | Biotech Hunter | Biotech Hunter